225 related articles for article (PubMed ID: 23464925)
1. Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration.
Luo L; Zhang X; Hirano Y; Tyagi P; Barabás P; Uehara H; Miya TR; Singh N; Archer B; Qazi Y; Jackman K; Das SK; Olsen T; Chennamaneni SR; Stagg BC; Ahmed F; Emerson L; Zygmunt K; Whitaker R; Mamalis C; Huang W; Gao G; Srinivas SP; Krizaj D; Baffi J; Ambati J; Kompella UB; Ambati BK
ACS Nano; 2013 Apr; 7(4):3264-75. PubMed ID: 23464925
[TBL] [Abstract][Full Text] [Related]
2. Targeted Intraceptor Nanoparticle for Neovascular Macular Degeneration: Preclinical Dose Optimization and Toxicology Assessment.
Zhang X; Bohner A; Bhuvanagiri S; Uehara H; Upadhyay AK; Emerson LL; Bondalapati S; Muddana SK; Fang D; Li M; Sandhu Z; Hussain A; Carroll LS; Tiem M; Archer B; Kompella U; Patil R; Ambati BK
Mol Ther; 2017 Jul; 25(7):1606-1615. PubMed ID: 28236576
[TBL] [Abstract][Full Text] [Related]
3. Development of gene therapy for treatment of age-related macular degeneration.
Askou AL
Acta Ophthalmol; 2014 Jul; 92 Thesis3():1-38. PubMed ID: 24953666
[TBL] [Abstract][Full Text] [Related]
4. [Novel approach for management of age-related macular degeneration--antiangiogenic therapy and retinal regenerative therapy].
Tamaki Y
Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):232-68; discussion 269. PubMed ID: 17402564
[TBL] [Abstract][Full Text] [Related]
5. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV.
Singh SR; Grossniklaus HE; Kang SJ; Edelhauser HF; Ambati BK; Kompella UB
Gene Ther; 2009 May; 16(5):645-59. PubMed ID: 19194480
[TBL] [Abstract][Full Text] [Related]
6. Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration.
Lambert NG; Zhang X; Rai RR; Uehara H; Choi S; Carroll LS; Das SK; Cahoon JM; Kirk BH; Bentley BM; Ambati BK
Exp Eye Res; 2016 Apr; 145():248-257. PubMed ID: 26775053
[TBL] [Abstract][Full Text] [Related]
7. AAV2 delivery of Flt23k intraceptors inhibits murine choroidal neovascularization.
Zhang X; Das SK; Passi SF; Uehara H; Bohner A; Chen M; Tiem M; Archer B; Ambati BK
Mol Ther; 2015 Feb; 23(2):226-34. PubMed ID: 25306972
[TBL] [Abstract][Full Text] [Related]
8. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
[TBL] [Abstract][Full Text] [Related]
9. Macrophage to myofibroblast transition contributes to subretinal fibrosis secondary to neovascular age-related macular degeneration.
Little K; Llorián-Salvador M; Tang M; Du X; Marry S; Chen M; Xu H
J Neuroinflammation; 2020 Nov; 17(1):355. PubMed ID: 33239022
[TBL] [Abstract][Full Text] [Related]
10. Aflibercept for neovascular age-related macular degeneration.
Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
[TBL] [Abstract][Full Text] [Related]
11. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial.
Rakoczy EP; Lai CM; Magno AL; Wikstrom ME; French MA; Pierce CM; Schwartz SD; Blumenkranz MS; Chalberg TW; Degli-Esposti MA; Constable IJ
Lancet; 2015 Dec; 386(10011):2395-403. PubMed ID: 26431823
[TBL] [Abstract][Full Text] [Related]
13. Adeno-associated vector (type 8)-mediated expression of soluble Flt-1 efficiently inhibits neovascularization in a murine choroidal neovascularization model.
Igarashi T; Miyake K; Masuda I; Takahashi H; Shimada T
Hum Gene Ther; 2010 May; 21(5):631-7. PubMed ID: 20053138
[TBL] [Abstract][Full Text] [Related]
14. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
15. Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches.
Ricci F; Bandello F; Navarra P; Staurenghi G; Stumpp M; Zarbin M
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153227
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema.
Gelfman CM; Grishanin R; Bender KO; Nguyen A; Greengard J; Sharma P; Nieves J; Kiss S; Gasmi M
J Ocul Pharmacol Ther; 2021 Apr; 37(3):181-190. PubMed ID: 33835848
[TBL] [Abstract][Full Text] [Related]
17. The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease.
Sidman RL; Li J; Lawrence M; Hu W; Musso GF; Giordano RJ; Cardó-Vila M; Pasqualini R; Arap W
Sci Transl Med; 2015 Oct; 7(309):309ra165. PubMed ID: 26468327
[TBL] [Abstract][Full Text] [Related]
18. Co-inhibition of PGF and VEGF blocks their expression in mononuclear phagocytes and limits neovascularization and leakage in the murine retina.
Balser C; Wolf A; Herb M; Langmann T
J Neuroinflammation; 2019 Feb; 16(1):26. PubMed ID: 30732627
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration.
Koo T; Park SW; Jo DH; Kim D; Kim JH; Cho HY; Kim J; Kim JH; Kim JS
Nat Commun; 2018 May; 9(1):1855. PubMed ID: 29748595
[TBL] [Abstract][Full Text] [Related]
20. Age-Related Macular Degeneration: A Review.
Fleckenstein M; Schmitz-Valckenberg S; Chakravarthy U
JAMA; 2024 Jan; 331(2):147-157. PubMed ID: 38193957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
